156 related articles for article (PubMed ID: 32307332)
1. Risk of adverse events in advanced hepatocellular carcinoma with immune checkpoint therapy: A systematic review and meta-analysis.
Yuan H; Mao J; Liu C; Fu H; Guo W; Ding G
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):845-854. PubMed ID: 32307332
[TBL] [Abstract][Full Text] [Related]
2. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
[TBL] [Abstract][Full Text] [Related]
3. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
[No Abstract] [Full Text] [Related]
4. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
[TBL] [Abstract][Full Text] [Related]
6. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
8. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis.
Balibegloo M; Nejadghaderi SA; Sadeghalvad M; Soleymanitabar A; Salehi Nezamabadi S; Saghazadeh A; Rezaei N
Int Immunopharmacol; 2021 Jul; 96():107796. PubMed ID: 34162158
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials.
Yuan H; Duan DD; Zhang YJ
Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102031. PubMed ID: 36261109
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
Kambhampati S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
[TBL] [Abstract][Full Text] [Related]
11. PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review.
Voutsadakis IA
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):505-510. PubMed ID: 31551142
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Yang TK; Yu YF; Tsai CL; Li HJ; Yang PS; Huang KW; Cheng JC
BMC Cancer; 2022 Oct; 22(1):1085. PubMed ID: 36271374
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
14. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
15. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qin Q; Wang J; Wang H
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
[TBL] [Abstract][Full Text] [Related]
16. Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Li X; Wan J; Wu Z; Tu J; Hu Y; Wu S; Lou L
Drug Des Devel Ther; 2018; 12():3043-3049. PubMed ID: 30271119
[TBL] [Abstract][Full Text] [Related]
17. Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review.
Zhang R; Wang F; You Z; Deng D; He J; Yan W; Quan J; Wang J; Yan S
J Cancer Res Clin Oncol; 2024 Feb; 150(2):82. PubMed ID: 38319412
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
Díaz-González Á; Sanduzzi-Zamparelli M; Sapena V; Torres F; LLarch N; Iserte G; Forner A; da Fonseca L; Ríos J; Bruix J; Reig M
Aliment Pharmacol Ther; 2019 Mar; 49(5):482-491. PubMed ID: 30695819
[TBL] [Abstract][Full Text] [Related]
19. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
[TBL] [Abstract][Full Text] [Related]
20. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
[Next] [New Search]